The European Medicines Agency (EMEA) has put out a survey to determine how information on clinical trials from EudraCT, the database maintained by the agency on behalf of the European Commission, can be made available to the general public.

Selected information from EudraCT will be accessible through the public information channel of the EudraCT website and through EudraPharm, the database on medicines approved in the European Union. Previously the EudraCT database was only open to the EMEA and the competent authorities of the EU member states.

In February, the European Commission published a guideline setting out the specific data fields of EudraCT to be made publicly available, such as information on trial protocols, objectives and scope as well as each Investigational Medicinal Product involved.

Following changes to European legislation, the EMEA is now in a position to follow through on that guidance, the agency noted. Its survey is published online and may be accessed and completed through the EMEA’s website, with a deadline of 23 June 2009.

“We are interested in knowing which aspects of this information are of most interest to you, how you might use this information and how you would want to access it, “ the agency commented, adding that responses to the survey “will help us to design a website that is appropriate for the needs of the public and other interested parties”.

The EudraCT database includes information on studies with at least one site in the EU, and which began in at least one member state following the transposition of the clinical trials Directive, 2001/20/EC. Its data fields are largely consistent with initiatives on clinical trial registries taken by international bodies such as the World Health Organization and the International Committee of Medical Journal Editors.